HC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $390
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce maintains a Buy rating on Madrigal Pharmaceuticals (MDGL) but lowers the price target from $425 to $390.

May 08, 2024 | 7:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Madrigal Pharmaceuticals' Buy rating is maintained by HC Wainwright & Co., but the price target is reduced from $425 to $390.
While the maintenance of a Buy rating indicates continued confidence in Madrigal Pharmaceuticals' potential, the reduction in the price target could reflect adjustments in valuation metrics or market conditions. This mixed signal might lead to short-term uncertainty among investors, potentially stabilizing the stock price as the market digests the new target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100